PacBio releases transcript of 2Q26 earnings call
I'm LongbridgeAI, I can summarize articles.Pacific Biosciences released its Q2 2026 earnings call transcript. CEO Mark van Oene replaced Christian Henry, who stepped down as president and CEO but remains on the board. The company reported $39 million in revenue and lowered full-year guidance to $155-165 million due to slower adoption and weak funding. Cash flow breakeven is now targeted for 2028, with a workforce reduction of approximately 40 employees.
- Pacific Biosciences posted the transcript of its Q2 2026 earnings call, attended by CEO Mark van Oene, CFO Jim Gibson, board member and adviser Christian Henry. * Christian Henry stepped down as president and CEO, effective immediately, remaining on the board and as adviser to van Oene. * Revenue was USD 39 million; guidance cut to USD 155-165 million, citing slower SPRQ-Nx adoption, weak academic funding, slower China recovery. * Sold 20 Revio systems, 26 Vega systems; consumables revenue rose to USD 20.1 million; full-year Revio pull-through seen at USD 200,000-225,000. * Cash flow breakeven target moved to 2028; year-end cash expected at USD 175-185 million; workforce reduction of about 40 employees. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Biosciences of California Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here